FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387403491> ?p ?o ?g. }

• W4387403491 abstract "Background Radiofrequency ablation (RFA) and chemotherapy are used to treat lung cancer or pulmonary metastases, but no direct comparison of overall survival (OS) has been published. The present study aimed to assess the OS of RFA and/or chemotherapy in patients with lung cancer or pulmonary metastases who were not candidates for surgical resection. Methods To identify relevant studies, the following databases were electronically searched from their inception to 31 March 2023: PubMed, Embase, Web of Science, Cochrane Library, Scopus, Ovid, ScienceDirect, SinoMed, China National Knowledge Infrastructure Database, Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Database, LILACS, ClinicalTrials.gov , and Chictr.org . Manual retrieval was also conducted. We used published hazard ratios (HRs) if available or estimates from other survival data. Results A total of 1,387 participants from 14 trials were included in the final analysis. Patients treated with RFA combined with chemotherapy significantly improved OS compared with those treated with chemotherapy alone [HR 0.50, 95% confidence interval (CI) 0.41–0.61; p &lt; 0.00001], with an absolute difference at 12 months of 29.6% (95% CI 23.7–35.5), at 24 months of 19.2% (95% CI 10.1–28.2), and at 36 months of 22.9% (95% CI 12.0–33.7). No statistically significant difference was observed in the subgroups of case type, cancer type, chemotherapy drugs, and tumor size. The HR for OS with RFA plus chemotherapy vs. RFA alone was 0.53 (95% CI 0.41–0.70; p &lt; 0.00001), corresponding to a 27.1% (95% CI 18.3–35.8), 31.0% (95% CI 19.9–41.9), and 24.9% (95% CI 15.0–34.7) absolute difference in survival at 12 months, 24 months, and 36 months, respectively. Subgroup analysis by geographic region and TNM stage showed that RFA combined with chemotherapy still significantly improved OS compared to RFA. The HR of RFA vs. chemotherapy was 0.98 (95% CI 0.60–1.60; p = 0.94), with an absolute difference at 12 months of 1.4% (95% CI -19.2 to 22.1), at 24 months of 7.8% (95% CI -11.3 to 26.8), and at 36 months of 0.3% (95% CI -13.2 to 13.8). The overall indirect comparison of OS for RFA vs. chemotherapy was 0.95 (95% CI 0.72–1.26; p = 0.74). Data on progression-free survival were not sufficiently reported. Conclusion RFA combined with chemotherapy might be a better treatment option for patients with lung cancer or pulmonary metastases than chemotherapy alone or RFA alone. The comparison between RFA and/or chemotherapy remains to be specifically tested. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=335032 , identifier CRD42022335032." @default.
• W4387403491 created "2023-10-07" @default.
• W4387403491 creator A5001292314 @default.
• W4387403491 creator A5003107322 @default.
• W4387403491 creator A5003367512 @default.
• W4387403491 creator A5006293284 @default.
• W4387403491 creator A5020377642 @default.
• W4387403491 creator A5034976239 @default.
• W4387403491 creator A5039013071 @default.
• W4387403491 creator A5079368105 @default.
• W4387403491 creator A5084690153 @default.
• W4387403491 date "2023-10-06" @default.
• W4387403491 modified "2023-10-07" @default.
• W4387403491 title "Survival after radiofrequency ablation and/or chemotherapy for lung cancer and pulmonary metastases: a systematic review and meta-analysis" @default.
• W4387403491 cites W174858683 @default.
• W4387403491 cites W1823472515 @default.
• W4387403491 cites W1915316305 @default.
• W4387403491 cites W1972140550 @default.
• W4387403491 cites W1975869469 @default.
• W4387403491 cites W1978882180 @default.
• W4387403491 cites W1993472319 @default.
• W4387403491 cites W2000069632 @default.
• W4387403491 cites W2023013236 @default.
• W4387403491 cites W2037139573 @default.
• W4387403491 cites W2042669918 @default.
• W4387403491 cites W2072710807 @default.
• W4387403491 cites W2088095316 @default.
• W4387403491 cites W2088371419 @default.
• W4387403491 cites W2101156795 @default.
• W4387403491 cites W2105400743 @default.
• W4387403491 cites W2110598415 @default.
• W4387403491 cites W2122548312 @default.
• W4387403491 cites W2134314702 @default.
• W4387403491 cites W2150358925 @default.
• W4387403491 cites W2166069569 @default.
• W4387403491 cites W2303758877 @default.
• W4387403491 cites W2396711138 @default.
• W4387403491 cites W2536288347 @default.
• W4387403491 cites W2536793344 @default.
• W4387403491 cites W2567362164 @default.
• W4387403491 cites W2740402187 @default.
• W4387403491 cites W2753691442 @default.
• W4387403491 cites W2792661551 @default.
• W4387403491 cites W2915804716 @default.
• W4387403491 cites W2964966490 @default.
• W4387403491 cites W2970684805 @default.
• W4387403491 cites W2987440458 @default.
• W4387403491 cites W3097220886 @default.
• W4387403491 cites W3118948948 @default.
• W4387403491 cites W3128646645 @default.
• W4387403491 cites W3174160636 @default.
• W4387403491 cites W4254013690 @default.
• W4387403491 doi "https://doi.org/10.3389/fimmu.2023.1240149" @default.
• W4387403491 hasPublicationYear "2023" @default.
• W4387403491 type Work @default.
• W4387403491 citedByCount "0" @default.
• W4387403491 crossrefType "journal-article" @default.
• W4387403491 hasAuthorship W4387403491A5001292314 @default.
• W4387403491 hasAuthorship W4387403491A5003107322 @default.
• W4387403491 hasAuthorship W4387403491A5003367512 @default.
• W4387403491 hasAuthorship W4387403491A5006293284 @default.
• W4387403491 hasAuthorship W4387403491A5020377642 @default.
• W4387403491 hasAuthorship W4387403491A5034976239 @default.
• W4387403491 hasAuthorship W4387403491A5039013071 @default.
• W4387403491 hasAuthorship W4387403491A5079368105 @default.
• W4387403491 hasAuthorship W4387403491A5084690153 @default.
• W4387403491 hasBestOaLocation W43874034911 @default.
• W4387403491 hasConcept C121608353 @default.
• W4387403491 hasConcept C126322002 @default.
• W4387403491 hasConcept C141071460 @default.
• W4387403491 hasConcept C143998085 @default.
• W4387403491 hasConcept C207103383 @default.
• W4387403491 hasConcept C2776256026 @default.
• W4387403491 hasConcept C2776478404 @default.
• W4387403491 hasConcept C2776694085 @default.
• W4387403491 hasConcept C2777377203 @default.
• W4387403491 hasConcept C2778902805 @default.
• W4387403491 hasConcept C44249647 @default.
• W4387403491 hasConcept C71924100 @default.
• W4387403491 hasConcept C95190672 @default.
• W4387403491 hasConceptScore W4387403491C121608353 @default.
• W4387403491 hasConceptScore W4387403491C126322002 @default.
• W4387403491 hasConceptScore W4387403491C141071460 @default.
• W4387403491 hasConceptScore W4387403491C143998085 @default.
• W4387403491 hasConceptScore W4387403491C207103383 @default.
• W4387403491 hasConceptScore W4387403491C2776256026 @default.
• W4387403491 hasConceptScore W4387403491C2776478404 @default.
• W4387403491 hasConceptScore W4387403491C2776694085 @default.
• W4387403491 hasConceptScore W4387403491C2777377203 @default.
• W4387403491 hasConceptScore W4387403491C2778902805 @default.
• W4387403491 hasConceptScore W4387403491C44249647 @default.
• W4387403491 hasConceptScore W4387403491C71924100 @default.
• W4387403491 hasConceptScore W4387403491C95190672 @default.
• W4387403491 hasFunder F4320329536 @default.
• W4387403491 hasLocation W43874034911 @default.
• W4387403491 hasOpenAccess W4387403491 @default.
• W4387403491 hasPrimaryLocation W43874034911 @default.
• W4387403491 hasRelatedWork W2099132737 @default.
• W4387403491 hasRelatedWork W2189666756 @default.
• W4387403491 hasRelatedWork W2351281209 @default.

• next